Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 7;8(1):002194.
doi: 10.12890/2021_002194. eCollection 2021.

Mesalazine-induced Hypersensitivity Pneumonitis

Francisca M Pereira  1 , Cristina Marques  1 , Teresa Boncoraglio  1 , Joana Esteves  1 , Marinha Silva  1 , Joana Braga  1 , Márcia Ribeiro  1
Affiliations

Mesalazine-induced Hypersensitivity Pneumonitis

Francisca M Pereira et al. Eur J Case Rep Intern Med. .

Abstract

A 57-year-old woman with Crohn's disease (ulcerative proctitis) treated with mesalazine (5-ASA) developed worsening respiratory distress and cough. The lack of response to antibiotics and the results of bronchoalveolar lavage led to the diagnosis of mesalazine-related hypersensitivity pneumonitis, an infrequent entity. Symptoms improved after discontinuation of mesalazine and the administration of corticosteroid therapy. The authors discuss the diagnosis and management of this rare condition.

Learning points: A diagnosis of mesalazine-related hypersensitivity pneumonitis should be considered when unexplained respiratory symptoms develop during treatment with mesalazine.It is important to distinguish pulmonary manifestations in patients with inflammatory bowel disease secondary to drug-related toxicity from the disease process itself.Amelioration of symptoms and improvement in imaging and lung function seem to occur only upon abrupt discontinuation of the drug; severe symptoms such as respiratory failure may justify corticosteroid therapy.

Keywords: Mesalazine; drug reaction; hypersensitivity pneumonitis; lung injury; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interests: The Authors declare that there are no competing interests.

Figures

Figure 1
Figure 1
Chest x-ray revealing interstitial heterogeneous diffuse infiltrate
Figure 2
Figure 2
Chest CT scan (axial view) showing bilateral ground-glass opacities, with sub-segmental consolidation in basal topography
Figure 3
Figure 3
Chest CT scan (coronal view) showing bilateral ground-glass opacities, with sub-segmental consolidation in basal topography
See this image and copyright information in PMC

References

    1. Huang PH, Kuo CJ, Lin CW, Cheng YM, Hu HC, Lin CY, et al. Mesalazine-related lung disease in a patient with ulcerative colitis: a case report. Medicine (Baltimore) 2018;97(48):3–6. - PMC - PubMed
    1. Kacprzak A, Siemion-Szcześniak I, Szturmowicz M, Bestry I, Langfort R, Kuś J. Pulmonary pathology in patients with ulcerative colitis treated with mesalazine—a challenging and complex diagnostic problem. Case series and literature review. Pneumonol Alergol Pol. 2014;82(4):368–376. - PubMed
    1. Kotsiou OS, Gourgoulianis KI. A case report of mesalazine-induced lung injury: a reversible drug side effect. Respir Med Case Rep. 2019;27:100865. - PMC - PubMed
    1. Fouka E, Stefanopoulo P, Dramba V, Bombotas D. Acute interstitial lung disease in a patient with ulcerative colitis: case report and literature review. Pneumon. 2012;25(3):320–324.
    1. Bitton A, Peppercorn MA, Hanrahan JP, Upton MP. Mesalamine-induced lung toxicity. Am J Gastroenterol. 1996;91(5):1039–1040. - PubMed

LinkOut - more resources